Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 22q Related Schwannomatosis Cn378756
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 22q Related Schwannomatosis CN378756 for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
22q Related Schwannomatosis Cn378756
A rare genetic condition linked to chromosome 22, causing multiple benign nerve tumors called schwannomas. Can cause pain and other symptoms. Managed with surgery and pain control.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
22q Related Schwannomatosis Cn378756
20-50
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
22q Related Schwannomatosis Cn378756
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
22q Related Schwannomatosis Cn378756
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
22q Related Schwannomatosis Cn378756
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
22q Related Schwannomatosis Cn378756
neurologic
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
22q Related Schwannomatosis Cn378756
oncology
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 22q-related-schwannomatosis-CN378756 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 22q Related Schwannomatosis Cn378756 | Discriminating power |
|---|---|---|---|
| Developmental delay | Often prominent from infancy, with neurologic impairment. | Not a typical presenting feature. | High |
| Seizures | Common and may be difficult to control. | Not characteristic; other causes should be considered. | High |
| Pain or nerve symptoms | Movement difficulty may occur, but tumor-related pain is not typical. | Pain, numbness, or weakness may relate to schwannomas. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Infant or young child with seizures and developmental delay
Early severe neurologic presentation fits the described metabolic disorder better.
Moderate
Suspected disorder of serine synthesis
Amino-acid testing and specialist metabolic evaluation are appropriate.
High
No evidence of nerve-sheath tumors
Absence of schwannomas makes the tumor condition less likely, but does not prove the metabolic diagnosis.
Moderate
Choose 22q Related Schwannomatosis Cn378756 when
Adult with multiple painful nerve tumors
This pattern aligns with schwannomatosis rather than early serine deficiency.
Moderate
Known or suspected chromosome 22-related predisposition
Genetic assessment can support the tumor diagnosis when clinically indicated.
Moderate
Onset in adulthood without infantile encephalopathy
Later onset favors schwannomatosis over the described metabolic disorder.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 22q Related Schwannomatosis Cn378756 | Interpretation |
|---|---|---|---|
| Plasma and CSF amino acids | Low serine may be found; exact cutoffs are not supplied. | No characteristic serine abnormality is described. | Abnormal amino acids suggest a metabolic disorder but require specialist confirmation. |
| Genetic testing | Pathogenic PHGDH variants may support the diagnosis. | Chromosome 22-related variants may be relevant. | Results must be interpreted with phenotype; a variant alone may not be diagnostic. |
| MRI or nerve imaging | May show nonspecific brain changes; tumors are not expected. | May identify schwannomas along nerves. | Imaging findings need correlation with symptoms and pathology when obtained. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Often severe and chronic, but individual course varies and is not fully established here.
- Factors
- Age at recognition, seizure burden, developmental impact, and response to care.
22q Related Schwannomatosis Cn378756
- Outcome
- Often moderate but chronic; tumor number, pain, and nerve effects vary.
- Factors
- Tumor location, growth, pain control, and surgical feasibility.
Time frame: Both are described as chronic; no reliable survival estimate is supplied.
Prognosis should be individualized; source data do not support exact outcomes.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Developmental delay, seizures, and movement difficulty may be severe. Focal weakness or sensory loss may occur from nerve compression. Mechanisms differ: metabolic brain dysfunction versus tumor-related nerve effects. |
| Pain | Not described as the main complication. Chronic or neuropathic pain may be significant. Pain management should be individualized; no dose is specified here. |
| Treatment-related effects | Supplementation and antiseizure therapy require monitoring. Surgery and pain treatment carry procedure-specific risks. Benefits and risks need clinician review; outcomes are not uniform. |
Patient education highlights
- HighDifferent conditions
These are unrelated rare disorders and should not be treated as interchangeable diagnoses.
- HighSpecialist care
Metabolic, neurology, genetics, or tumor specialists may be needed depending on findings.
- MediumWarning symptoms
New seizures, worsening weakness, severe pain, or rapid change should prompt urgent clinical review.